HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Sept. 18, 2020 (HealthDay News) -- More than half of patients have experienced changes in their lung cancer treatment plan as a result of the COVID-19 pandemic, according to a research letter published online Sept. 17 in JAMA Oncology.
Arielle Elkrief, M.D., from the McGill University Health Center in Montreal, and colleagues examined changes in lung cancer treatment during the COVID-19 pandemic. The extent of changes in the treatment plan were described, and types of changes observed were qualified.
Data were included for 275 patients, of whom 211 were receiving active treatment. The researchers found that 57 percent (121 patients) of those receiving active treatment experienced at least one change in their lung cancer treatment plan; 9.0 percent (19 patients) had more than one change. Most changes included delay or cessation of palliative chemotherapy (39.7 and 14.9 percent, respectively). There was a mean of 36 days for time to resumption of chemotherapy; four patients stopped palliative treatment permanently. Overall, 26.4 percent of patients had changes in dosing and schedule. Delays in adjuvant chemotherapy administration occurred in 2.5 percent of patients, with a mean delay of 42 days. Deferrals or cancellations of surveillance visits owing to the pandemic were experienced by 6.6 percent of patients.
"Our study reinforces that all oncology clinics should track these changes occurring in cancer care because it will become important to evaluate the effect of these changes on clinical outcomes," the authors write.
One author disclosed financial ties to AstraZeneca.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 25, 2022